CClinicalTrials.gg
Sign In
Status unknownNCT00599482Updated Jan 5, 2009

Far Infrared Radiation for Sickle Cell Pain Management

A Phase 1 interventional study of Far Infrared Radiation (5μm to 20μm wavelength) in Anemia, Sickle Cell, sponsored by GAAD Medical Research Institute Inc.. Status unknown at 1 site in Canada. Per ClinicalTrials.gov, last updated 2009-01-05.

Sponsored by GAAD Medical Research Institute Inc. · Phase 1, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Jan 2009), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Sex
All
01

Study summary

Most patients with sickle-cell disease have periodic intensely painful episodes. To manage this pain, we are proposing the drinking of at least 500 mL of water followed by far infrared radiation.

Read the detailed description

Painful sickle cell crises are treated with hydration and analgesics. Ischemia is an absolute or relative shortage of the blood supply to an organ. Relative shortage means the mismatch of blood supply (oxygen delivery) and blood request for adequate oxygenation of tissue.

It is hereby postulated that far infrared radiation of the body will promote blood and oxygen supply to the affected tissues. In addition, the analgesic properties of far infrared will alleviate pain due to the crisis.

02

Conditions studied

  • Anemia, Sickle Cell

Browse trials for

Keywords

  • HEMOGLOBIN SC DISEASE
  • HEMOGLOBIN C DISEASE
  • SICKLE CELL TRAIT
  • THALASSEMIA
03

In context

Anemia, Sickle Cell

1,103 studies on the registry are indexed under Anemia, Sickle Cell; 235 are open to participants now.

This study's planned enrollment of 10 is below the median of 40 across 750 interventional studies indexed under Anemia, Sickle Cell.

Browse Anemia, Sickle Cell studies →

Lead sponsor

GAAD Medical Research Institute Inc. is the lead sponsor of 21 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • People with sickle cell disease

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    1

    Far Infrared Radiation

    Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Interventions

  • RadiationFar Infrared Radiation (5μm to 20μm wavelength)

    Far infrared radiation for 30 to 40 minutes during each session.

06

What researchers measure

Primary outcomes

  1. Pain Management

    Time frame: 40 minutes

07

Study locations

1 site
  • The Centre for Incurable Diseases
    Mississauga, Ontario L5R 3G9, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00599482
Lead sponsor
GAAD Medical Research Institute Inc.
First posted
Jan 23, 2008
Start date
Jan 2008
Primary completion
Sep 2008 (estimated)
Completion
Jan 2009 (estimated)
Last update
Jan 5, 2009

Study contacts

Ken Nedd, M.D.
study chair · GAAD Medical Research Institute Inc.
Kwasi Donyina, Ph.D.
study director · GAAD Medical Research Institute Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Anemia, Sickle Cell→

Other studies from this sponsor

GAAD Medical Research Institute Inc.

Start the discussion